02 May 2013
Class 4 medicines defect information
Caution in use
Distribute to pharmacy level
Ativan Injection 4mg/ml
|Batch number||Expiry date||Pack size||First distributed|
|4004||July 2013||10 x 1ml||8 October 2012|
|4005||July 2013||10 x 1ml||18 December 2012|
|4007||September 2013||10 x 1ml||5 February 2013|
|4009||December 2013||10 x 1ml||9 April 2013|
Pfizer Limited has informed us that during routine testing and subsequent investigation of some unreleased batches of Ativan Injection which had been subjected to automated visible inspection during manufacture, a very small number of ampoules containing glass particles were identified. The incidence rate, at <0.01%, is very low. The batches listed in the above table have already been released to the market and whilst there is no evidence to suggest that they are affected by this issue (Pfizer has received no customer complaints or adverse reaction reports related to this matter), it cannot be ruled out.
Since Pfizer is the only UK marketing authorisation holder for this product and there is no alternative stock available, these batches are not at present being recalled. As a precaution in the meantime, however, the following procedures should be followed prior to administration:
- vsually inspect the contents of each ampoule carefully for particulate matter. Reject the ampoule if any particulate matter is discovered - please report any findings to Pfizer Medical Information on 01304 616161
- follow all recommended steps for product dilution in accordance with the product information
- pre-filter the product prior to administration by using 5 micron filter needles or filter straws when drawing it into the syringe
- remove the filter needle or filter straw from the syringe and replace with a new sterile needle for administration
For medical information enquiries, please contact Pfizer Medical Information on 01304 616161.
For any stock related enquiries, please contact Pfizer’s Customer Contact Centre on 0845 608 8866 and select option 2.
Recipients of this drug alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.